PDL BioPharma, Inc. Finite-Lived Intangible Assets, Net
PDL BioPharma, Inc. had Finite-Lived Intangible Assets, Net of $12.55 million as of 2020-06-30, per its 10-Q filed 2020-08-07.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2021-03-29
- 2020-06-30: Finite-Lived Intangible Assets, Net $12.55M.
- 2020-03-31: Finite-Lived Intangible Assets, Net $12.88M.
- 2019-12-31: Finite-Lived Intangible Assets, Net $13.19M; Finite-Lived Intangible Assets, Net as first filed $23.30M.
- 2019-09-30: Finite-Lived Intangible Assets, Net $47.35M.
| Period end | Finite-Lived Intangible Assets, Net | Finite-Lived Intangible Assets, Net as first filed |
|---|---|---|
| 2020-06-30 | $12.55M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $12.88M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $13.19M 10-K · filed 2021-03-29 | $23.30M 10-K · filed 2020-03-11 |
| 2019-09-30 | $47.35M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $50.45M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $49.75M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $13.70M 8-K · filed 2020-06-29 | $51.32M 10-K · filed 2019-03-15 |
| 2018-09-30 | $52.90M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $54.47M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $213.19M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $215.82M 10-K · filed 2019-03-15 | |
| 2017-09-30 | $222.07M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $228.35M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $222.53M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $228.54M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $234.56M 10-Q · filed 2016-11-03 | |
| 2014-03-31 | $223.75M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $235.68M 10-Q · filed 2014-05-12 |